A tiny fungal molecule being studied to fight cryptococcal infections
An extracellular vesicle component as a candidate to control cryptococcosis.
Researchers are testing whether a small peptide from fungal vesicles (IPI) can help control cryptococcal infections in people with weakened immune systems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fundacao Oswaldo Cruz NIH-funded |
| Lab location | 1 site (Rio de Janeiro, BRAZIL) |
| Project ID | NIH-11258477 on NIH RePORTER |
What this research studies
Researchers found a tiny peptide called IPI inside fungal extracellular vesicles that stopped Cryptococcus infection in an insect model. They will study how IPI affects the fungus and the host by doing lab experiments and animal-model work focused on the enzyme DPP4, which influences fungal virulence and host metabolism. The team will use molecular and cellular tests to map how IPI changes fungal behavior and host immune responses. These experiments aim to show whether IPI or related approaches could be developed into new antifungal strategies.
Who could benefit from this research
Good fit: People at high risk for cryptococcal disease—for example, those with advanced HIV, transplant recipients, or others with weakened immunity—are the population that might benefit from eventual therapies stemming from this work.
Not a fit: Healthy people without risk factors for cryptococcal infection are unlikely to benefit directly from this preclinical research, and it is not an immediate treatment for advanced meningitis right now.
Why it matters
Potential benefit: If successful, this work could point to a new way to prevent or treat cryptococcosis, especially for people with weakened immune systems.
How similar studies have performed: Early laboratory work showed IPI controlled cryptococcal infection in an invertebrate model, but it has not yet been tested in mammals or humans.
Where this research is happening
Rio de Janeiro, BRAZIL
- Fundacao Oswaldo Cruz — Rio de Janeiro, Brazil (Active)
Researchers
- Principal investigator: Rodrigues, Marcio Lourenco — Fundacao Oswaldo Cruz
- Study coordinator: Rodrigues, Marcio Lourenco
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.